- Home
- YSXT vs SKYE Comparison
YSXT vs SKYE Comparison
Compare YSXT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | SKYE |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | United States |
| Employees | 39 | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 23.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | YSXT | SKYE |
|---|---|---|
| Price | $1.20 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 230.2K | ★ 331.8K |
| Earning Date | 02-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.57 |
| 52 Week High | $9.90 | $5.75 |
Technical Indicators
Market Signals| Indicator | YSXT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 52.16 |
| Support Level | $1.08 | $0.68 |
| Resistance Level | $1.51 | $0.83 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 20.33 | 84.95 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.